Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma Holdings Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	62.69	67.45	121.97	67.27	37.6	19.52
Short-Term Investments	24.66	5	0	35.16	96.19	56.03
Cash & Cash Equivalents	87.35	72.45	121.97	102.43	133.79	75.55
Cash Growth	-8.15%	-40.60%	19.07%	-23.44%	77.09%	-32.92%
Receivables	37.41	39.2	30.83	17.46	6.88	4.69
Inventory	40.88	38.84	24.74	18.12	8.35	2.18
Other Current Assets	7.64	5.78	9.29	4.59	3.2	5.07
Total Current Assets	173.28	156.26	186.82	142.6	152.21	87.48
Property, Plant & Equipment	28.81	29.18	9.51	6.63	6.71	7.85
Long-Term Investments	0	0	0	0	0	13.23
Goodwill and Intangibles	129.91	132.62	143.47	154.31	0	0
Other Long-Term Assets	4.61	4.54	4.73	0.83	0.23	0.42
Total Long-Term Assets	163.34	166.34	157.7	161.77	6.94	21.5
Total Assets	336.62	322.6	344.52	304.36	159.15	108.99
Accounts Payable	7.09	11.57	4.61	8.92	3.12	5.6
Current Debt	4.62	3.5	1.58	0	0	0
Other Current Liabilities	61.37	80.13	67.44	70.12	25.09	21.74
Total Current Liabilities	73.08	95.19	73.62	79.04	28.21	27.34
Long-Term Debt	264.07	225.7	196.48	88.07	87.02	58.31
Other Long-Term Liabilities	8.64	8.5	29.24	42.02	10.16	8.91
Total Long-Term Liabilities	272.71	234.19	225.71	130.09	97.18	67.21
Total Liabilities	345.79	329.38	299.34	209.13	125.39	94.55
Total Debt	268.7	229.19	198.06	88.07	87.02	58.31
Debt Growth	35.42%	15.72%	124.89%	1.20%	49.25%	82.83%
Retained Earnings	-636.01	-617.03	-554.77	-460.11	-337.39	-246.25
Comprehensive Income	-0.04	-0.03	-0.02	-0.03	0.01	0.04
Shareholders' Equity	-9.18	-6.78	45.19	95.23	33.76	14.44
Net Cash / Debt	-181.34	-156.74	-76.09	14.37	46.77	17.24
Net Cash / Debt Growth	-	-	-	-69.28%	171.21%	-78.64%
Net Cash Per Share	-1.29	-1.14	-0.56	0.18	1.10	0.66
Working Capital	100.2	61.07	113.2	63.56	124.01	60.15
Book Value Per Share	-0.07	-0.05	0.33	1.21	0.79	0.55

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).